• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肾细胞肿瘤的国际泌尿病理学会(ISUP)分期、分级及分类系统

The ISUP system of staging, grading and classification of renal cell neoplasia.

作者信息

Samaratunga Hemamali, Gianduzzo Troy, Delahunt Brett

机构信息

Aquesta Pathology, Brisbane, Queensland, Australia; University of Queensland, Brisbane, Queensland, Australia; Wesley Hospital, Brisbane, Queensland, Australia; Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand.

出版信息

J Kidney Cancer VHL. 2014 Jul 20;1(3):26-39. doi: 10.15586/jkcvhl.2014.11. eCollection 2014.

DOI:10.15586/jkcvhl.2014.11
PMID:28326247
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5345524/
Abstract

There have been significant changes in the staging, classification and grading of renal cell neoplasia in recent times. Major changes have occurred in our understanding of extra-renal extension by renal cell cancer and how gross specimens must be handled to optimally display extra-renal spread. Since the 1981 World Health Organization (WHO) classification of renal tumors, in which only a handful of different entities were reported, many new morphological types have been described in the literature, resulting in 50 different entities reported in the 2004 WHO classification. Since 2004, further new entities have been recognized and reported necessitating an update of the renal tumor classification. There have also been numerous grading systems for renal cell carcinoma with Fuhrman grading, the most widely used system. In recent times, the prognostic value and the applicability of the Fuhrman grading system in practice has been shown to be, at best, suboptimal. To address these issues and to recommend reporting guidelines, the International Society of Urological Pathology (ISUP) undertook a review of adult renal neoplasia through an international consensus conference in Vancouver in 2012. The conduct of the conference was based upon evidence from the literature and the current practice amongst recognized experts in the field. Working groups selected to deal with key topics evaluated current data and identified points of controversy. A pre-meeting survey of the ISUP membership was followed by the consensus conference at which a formal ballot was taken on each key issue. A 65% majority vote was taken as consensus. This review summarizes the outcome and recommendations of this conference with regards to staging, classification and grading of renal cell neoplasia.

摘要

近年来,肾细胞肿瘤的分期、分类和分级发生了重大变化。我们对肾细胞癌肾外扩展的理解以及如何处理大体标本以最佳显示肾外扩散方面发生了重大变化。自1981年世界卫生组织(WHO)对肾肿瘤进行分类(当时仅报告了少数几种不同类型)以来,文献中描述了许多新的形态学类型,导致2004年WHO分类中报告了50种不同类型。自2004年以来,又识别并报告了更多新类型,因此有必要更新肾肿瘤分类。肾细胞癌也有众多分级系统,其中Fuhrman分级是使用最广泛的系统。近年来,Fuhrman分级系统在实际应用中的预后价值和适用性已被证明充其量只是次优的。为了解决这些问题并推荐报告指南,国际泌尿病理学会(ISUP)于2012年在温哥华通过一次国际共识会议对成人肾肿瘤进行了综述。该会议依据文献证据和该领域公认专家的当前实践开展。被选来处理关键主题的工作组评估了当前数据并确定了争议点。在ISUP成员的会前调查之后召开了共识会议,会上对每个关键问题进行了正式投票。以65%的多数票作为达成共识的标准。本综述总结了此次会议关于肾细胞肿瘤分期、分类和分级的结果及建议。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7caf/5345524/92fdade805d6/jkcvhl-1-26-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7caf/5345524/03e783f7aaa6/jkcvhl-1-26-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7caf/5345524/3e40c0f68df1/jkcvhl-1-26-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7caf/5345524/ca7aaf681ef9/jkcvhl-1-26-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7caf/5345524/0e8e1fb495c7/jkcvhl-1-26-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7caf/5345524/85b9e6e08b3a/jkcvhl-1-26-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7caf/5345524/aa23c5536326/jkcvhl-1-26-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7caf/5345524/3ed8e1e33610/jkcvhl-1-26-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7caf/5345524/92fdade805d6/jkcvhl-1-26-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7caf/5345524/03e783f7aaa6/jkcvhl-1-26-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7caf/5345524/3e40c0f68df1/jkcvhl-1-26-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7caf/5345524/ca7aaf681ef9/jkcvhl-1-26-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7caf/5345524/0e8e1fb495c7/jkcvhl-1-26-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7caf/5345524/85b9e6e08b3a/jkcvhl-1-26-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7caf/5345524/aa23c5536326/jkcvhl-1-26-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7caf/5345524/3ed8e1e33610/jkcvhl-1-26-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7caf/5345524/92fdade805d6/jkcvhl-1-26-g008.jpg

相似文献

1
The ISUP system of staging, grading and classification of renal cell neoplasia.肾细胞肿瘤的国际泌尿病理学会(ISUP)分期、分级及分类系统
J Kidney Cancer VHL. 2014 Jul 20;1(3):26-39. doi: 10.15586/jkcvhl.2014.11. eCollection 2014.
2
Clear cell renal cell carcinoma: validation of World Health Organization/International Society of Urological Pathology grading.透明细胞肾细胞癌:世界卫生组织/国际泌尿病理学会分级的验证。
Histopathology. 2017 Dec;71(6):918-925. doi: 10.1111/his.13311. Epub 2017 Oct 2.
3
The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia.国际泌尿病理学会(ISUP)温哥华肾脏肿瘤分类。
Am J Surg Pathol. 2013 Oct;37(10):1469-89. doi: 10.1097/PAS.0b013e318299f2d1.
4
Contemporary Gleason Grading of Prostatic Carcinoma: An Update With Discussion on Practical Issues to Implement the 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma.当代前列腺癌的Gleason分级:结合对实施2014年国际泌尿病理学会(ISUP)前列腺癌Gleason分级共识会议实际问题的讨论进行更新
Am J Surg Pathol. 2017 Apr;41(4):e1-e7. doi: 10.1097/PAS.0000000000000820.
5
[Renal tumors: The International Society of Urologic Pathology (ISUP) 2012 consensus conference recommendations].[肾肿瘤:国际泌尿病理学会(ISUP)2012年共识会议推荐意见]
Ann Pathol. 2014 Dec;34(6):448-61. doi: 10.1016/j.annpat.2014.10.003. Epub 2014 Nov 18.
6
[Vancouver classification of renal tumors: Recommendations of the 2012 consensus conference of the International Society of Urological Pathology (ISUP)].[肾肿瘤的温哥华分类:国际泌尿病理学会(ISUP)2012年共识会议的建议]
Pathologe. 2015 May;36(3):310-6. doi: 10.1007/s00292-014-2030-z.
7
Verification of the International Society of Urological Pathology recommendations in Japanese patients with clear cell renal cell carcinoma.验证国际泌尿病理学会建议在日本透明细胞肾细胞癌患者中的应用。
Int J Oncol. 2018 Apr;52(4):1139-1148. doi: 10.3892/ijo.2018.4294. Epub 2018 Feb 28.
8
Advances in renal neoplasia: recommendations from the 2012 International Society of Urological Pathology Consensus Conference.肾肿瘤学进展:2012 年国际泌尿病理学会共识会议的建议。
Urology. 2014 May;83(5):969-74. doi: 10.1016/j.urology.2014.02.004. Epub 2014 Mar 22.
9
[WHO classification 2016 and first S3 guidelines on renal cell cancer: What is important for the practice?].[《2016年世界卫生组织分类及肾细胞癌首个S3指南:对临床实践而言什么是重要的?》]
Pathologe. 2016 Mar;37(2):127-33. doi: 10.1007/s00292-016-0144-1.
10
[The WHO/ISUP grading system for renal carcinoma].[世界卫生组织/国际泌尿病理学会肾癌分级系统]
Pathologe. 2016 Jul;37(4):355-60. doi: 10.1007/s00292-016-0171-y.

引用本文的文献

1
Case Report: Complete response with combination oncolytic virus immunotherapy in a patient with stage IV renal cell carcinoma-a promising innovative approach.病例报告:IV期肾细胞癌患者采用溶瘤病毒免疫联合疗法实现完全缓解——一种有前景的创新方法。
Front Oncol. 2025 Aug 7;15:1631155. doi: 10.3389/fonc.2025.1631155. eCollection 2025.
2
Development of a prognostic risk model for clear cell renal cell carcinoma by systematic evaluation of DNA methylation markers: an update after ISUP/WHO 2022 classification.通过对DNA甲基化标志物的系统评估建立透明细胞肾细胞癌的预后风险模型:ISUP/WHO 2022分类后的更新
J Pathol Clin Res. 2025 Sep;11(5):e70030. doi: 10.1002/2056-4538.70030.
3

本文引用的文献

1
International Society of Urological Pathology grading and other prognostic factors for renal neoplasia.国际泌尿病理学会肾脏肿瘤分级和其他预后因素。
Eur Urol. 2014 Nov;66(5):795-8. doi: 10.1016/j.eururo.2014.05.027. Epub 2014 Jun 2.
2
Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.多韦替尼对比索拉非尼用于转移性肾细胞癌三线靶向治疗:一项开放标签、随机、III 期临床试验。
Lancet Oncol. 2014 Mar;15(3):286-96. doi: 10.1016/S1470-2045(14)70030-0. Epub 2014 Feb 17.
3
Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.
Development and validation of a nomogram combined pre-operative quantitative MR parameters for the prediction of pathological WHO/ISUP grade in clear cell renal cell carcinoma.
用于预测透明细胞肾细胞癌病理WHO/ISUP分级的列线图联合术前定量MR参数的开发与验证
World J Urol. 2025 Aug 9;43(1):480. doi: 10.1007/s00345-025-05864-2.
4
Deep learning model for grading carcinoma with Gini-based feature selection and linear production-inspired feature fusion.基于基尼系数的特征选择和线性生成启发式特征融合的癌症分级深度学习模型。
Sci Rep. 2025 Jul 1;15(1):21225. doi: 10.1038/s41598-025-00217-w.
5
Occurrence of papillary renal cell carcinoma and clear cell renal carcinoma in a patient: A unique case report.一名患者同时发生乳头状肾细胞癌和透明细胞肾细胞癌:一例独特病例报告。
Medicine (Baltimore). 2025 May 2;104(18):e42312. doi: 10.1097/MD.0000000000042312.
6
[Molecularly defined renal cell carcinomas].[分子定义的肾细胞癌]
Pathologie (Heidelb). 2025 Feb;46(1):5-12. doi: 10.1007/s00292-024-01408-4. Epub 2025 Jan 27.
7
[Histomorphologically defined renal cell carcinomas 2025 : Current WHO classification and emerging future subtypes].[组织形态学定义的肾细胞癌2025:当前世界卫生组织分类及未来新兴亚型]
Pathologie (Heidelb). 2025 Feb;46(1):13-20. doi: 10.1007/s00292-024-01406-6. Epub 2025 Jan 16.
8
Radiomics Machine Learning Analysis of Clear Cell Renal Cell Carcinoma for Tumour Grade Prediction Based on Intra-Tumoural Sub-Region Heterogeneity.基于肿瘤内亚区域异质性的透明细胞肾细胞癌肿瘤分级预测的影像组学机器学习分析
Cancers (Basel). 2024 Apr 10;16(8):1454. doi: 10.3390/cancers16081454.
9
Underlying mechanisms of novel cuproptosis-related dihydrolipoamide branched-chain transacylase E2 (DBT) signature in sunitinib-resistant clear-cell renal cell carcinoma.新型铜死亡相关二氢硫辛酰胺支链转酰基酶 E2(DBT)标志物在舒尼替尼耐药肾透明细胞癌中的潜在机制。
Aging (Albany NY). 2024 Feb 1;16(3):2679-2701. doi: 10.18632/aging.205504.
10
Deep learning-assisted survival prognosis in renal cancer: A CT scan-based personalized approach.深度学习辅助的肾癌生存预后:基于CT扫描的个性化方法。
Heliyon. 2024 Jan 12;10(2):e24374. doi: 10.1016/j.heliyon.2024.e24374. eCollection 2024 Jan 30.
随机 III 期试验:替西罗莫司对比索拉非尼作为舒尼替尼治疗转移性肾细胞癌后的二线治疗。
J Clin Oncol. 2014 Mar 10;32(8):760-7. doi: 10.1200/JCO.2013.50.3961. Epub 2013 Dec 2.
4
A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC).一项多靶点酪氨酸激酶抑制剂仑伐替尼(E7080)联合依维莫司治疗转移性肾细胞癌(RCC)的 1b 期临床试验。
Cancer Chemother Pharmacol. 2014 Jan;73(1):181-9. doi: 10.1007/s00280-013-2339-y. Epub 2013 Nov 5.
5
Renal tumors: diagnostic and prognostic biomarkers.肾脏肿瘤:诊断和预后生物标志物。
Am J Surg Pathol. 2013 Oct;37(10):1518-31. doi: 10.1097/PAS.0b013e318299f12e.
6
Handling and staging of renal cell carcinoma: the International Society of Urological Pathology Consensus (ISUP) conference recommendations.肾细胞癌的处理和分期:国际泌尿病理学会共识(ISUP)会议建议。
Am J Surg Pathol. 2013 Oct;37(10):1505-17. doi: 10.1097/PAS.0b013e31829a85d0.
7
The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters.国际泌尿病理学会(ISUP)肾细胞癌分级系统及其他预后参数。
Am J Surg Pathol. 2013 Oct;37(10):1490-504. doi: 10.1097/PAS.0b013e318299f0fb.
8
The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia.国际泌尿病理学会(ISUP)温哥华肾脏肿瘤分类。
Am J Surg Pathol. 2013 Oct;37(10):1469-89. doi: 10.1097/PAS.0b013e318299f2d1.
9
International Society of Urological Pathology (ISUP) consensus conference on renal neoplasia: rationale and organization.国际泌尿病理学会(ISUP)肾肿瘤共识会议:基本原理与组织架构
Am J Surg Pathol. 2013 Oct;37(10):1463-8. doi: 10.1097/PAS.0b013e318299f14a.
10
Renal lymph nodes for tumor staging: appraisal of 871 nephrectomies with examination of hilar fat.肾淋巴结用于肿瘤分期:871 例肾切除术伴 hilar 脂肪检查的评估。
Arch Pathol Lab Med. 2013 Nov;137(11):1584-90. doi: 10.5858/arpa.2012-0485-OA. Epub 2013 May 7.